China NMPA Product Recall - Monitor defibrillator

The National Medical Products Administration (NMPA) announced a Class II voluntary recall initiated by Philips Medical Systems, through its entity Philips (China) Investment Co., Ltd., concerning certain monitored defibrillators (Registration Certificate No.: 20163214004). Published on July 12, 2017, the recall addresses a critical safety concern. The primary issue stems from a potential defect within a gas discharge tube (GDT) component of the affected devices. This defect has the potential to generate significant electrocardiogram (ECG) noise on the electrode pads. Such interference could severely impair a user's ability to accurately identify shockable cardioversion rhythms, posing a direct risk to patient safety. The inability to correctly assess cardiac rhythms can lead to delayed or inappropriate treatment in life-threatening situations. In response to this potential hazard, Philips Medical Systems has proactively undertaken a voluntary recall of these specific monitored defibrillators. The Class II classification indicates that the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The detailed scope, including specific registration numbers, specifications, and batch numbers, is available in the "Medical Device Recall Event Report Form" attachment, managed under the NMPA's regulatory oversight. This action underscores the company's commitment to patient safety and adherence to NMPA's medical device regulations.